Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.
Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.
复制标题
乳腺癌治疗的演变：乳腺肿瘤激酶在乳腺癌中的作用以及乳腺肿瘤激酶靶向治疗的希望。
DOI：
--
复制
发表时间：
2014
影响因子：
2.8
通讯作者：
A. Harvey
中科院分区：
文献类型：
--
作者：
H. Hussain;A. Harvey
近几十年来，乳腺癌的检测和治疗有了显著的改善。然而，仍然需要开发更有效的治疗技术，这些技术是患者特异性的，具有降低的毒性，从而进一步增加患者的总生存期;还需要保持在理解复发、耐药和扩散方面的持续进展。对乳腺癌病理学、分子生物学和进展的更好理解以及对参与乳腺癌肿瘤发生和转移的一些潜在因素的鉴定导致了新的治疗靶点的鉴定。多年来，人们对乳腺肿瘤激酶（Brk）（也称为蛋白酪氨酸激酶6）的兴趣已经上升;研究领域已经发展，并且Brk已经被描述为与酪氨酸激酶抑制以及其激酶非依赖性活性的破坏有关的理想治疗靶点。本次审查将概述目前的“状态发挥”方面的靶向治疗乳腺癌，以及讨论Brk的作用的过程中潜在的肿瘤的发展和转移，其潜在的治疗靶点在乳腺癌。
There have been significant improvements in the detection and treatment of breast cancer in recent decades. However, there is still a need to develop more effective therapeutic techniques that are patient specific with reduced toxicity leading to further increases in patients' overall survival; the ongoing progress in understanding recurrence, resistant and spread also needs to be maintained. Better understanding of breast cancer pathology, molecular biology and progression as well as identification of some of the underlying factors involved in breast cancer tumourgenesis and metastasis has led to the identification of novel therapeutic targets. Over a number of years interest has risen in breast tumour kinase (Brk) also known as protein tyrosine kinase 6; the research field has grown and Brk has been described as a desirable therapeutic target in relation to tyrosine kinase inhibition as well as disruption of its kinase independent activity. This review will outline the current "state of play" with respect to targeted therapy for breast cancer, as well as discussing Brk's role in the processes underlying tumour development and metastasis and its potential as a therapeutic target in breast cancer.
登录
查看更多内容
DOI：
--
发表时间：
2002-02
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
F. Meric;Wei‐Ping Lee;A. Sahin;Haixia Zhang;H. Kung;M. Hung
通讯作者：
F. Meric;Wei‐Ping Lee;A. Sahin;Haixia Zhang;H. Kung;M. Hung
影响因子：
64.5
作者：
H. Clevers
通讯作者：
H. Clevers
影响因子：
4.6
作者：
Quynh T. Tran;Lawrence H Kennedy;Sandra Leon Carrion;Sridevi Bodreddigari;S. Goodwin;C. H. Sutter;T. Sutter
通讯作者：
Quynh T. Tran;Lawrence H Kennedy;Sandra Leon Carrion;Sridevi Bodreddigari;S. Goodwin;C. H. Sutter;T. Sutter
影响因子：
4
作者：
B. Mayer
通讯作者：
B. Mayer
影响因子：
29.4
作者：
Haegebarth A;Perekatt AO;Bie W;Gierut JJ;Tyner AL
通讯作者：
Tyner AL